Section A: Basic Chemotherapy Principles

1. Simon R, Norton L: The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens, Nat Clin Pract Oncol 3:406, 2006. Medline abstracts
2. Kaufman DC, Chabner BA: Clinical strategies for cancer treatment: the role of drugs. In Chabner BA, Longo DL (eds): Cancer chemotherapy and biotherapy. Philadelphia, 2001, Lippincott, Williams & Wilkins.
3. Skipper HE, Schabel FM Jr, Mellet LB, et al: Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules, Cancer Chemother Rep 54:431, 1950.
4. Chu E, DeVita VT: Principles of medical oncology. In DeVita VT, Hellman S, Rosenberg SA (eds): Cancer principles and practice of oncology. Philadelphia, 2005, Lippincott, Williams & Wilkins.
5. Howard A, Pelc SR: Nuclear incorporation of p32 as demonstrated by autoradiographs, Exp Cell Res 2:178, 1951.
6. Reed SI: Cell cycle. In DeVita VT, Hellman S, Rosenberg SA (eds): Cancer principles and practice of oncology. Philadelphia, 2005, Lippincott, Williams & Wilkins.
7. Collins VP, Loeffler RK, Tivey H: Observations on growth rates of human tumors, Am J Roentgenol Radium Ther Nucl Med 76:988, 1956. Medline abstracts
8. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate, Cancer Treat Rep 63:172, 1979. Medline abstracts
9. DeVita VT, Schein PS: The use of drugs in combination for the treatment of cancer: rationale and results, N Engl J Med 288:998, 1973. Medline abstracts

Section B: Chemotherapy Drug Interactions

1. Baquiran DC, Gallagher J: Lippincott’s cancer chemotherapy handbook. Philadelphia, 1998, Lippincott-Raven.
2. Chabner BA, Longo DL: Cancer chemotherapy and biotherapy: principles and practice, ed 3. Philadelphia, 2001, Lippincott, Williams & Wilkins.
3. Dorr RT: Incompatibilities with parenteral anticancer drugs, Am J Intraven Ther 6(2):44, 1979.
4. Dorr RT, Fritz WL: Drug interactions. In Cancer chemotherapy handbook. New York, 1980, Elsevier.
5. Dorr RT, Von Hoff DD: Cancer chemotherapy handbook, ed 2. Norwalk, 1994, Appleton & Lange.
6. Griffin JP, D’Arcy PF: Antineoplastic agents: a manual of adverse drug interactions, ed 3. Bristol, 1984, Wright.
7. Henry CJ, Brewer WJ: Drug interactions with antineoplastic agents. In Current Veterinary Therapy XII. Philadelphia, 1995, WB Saunders.
8. McEvoy GK (ed): Antineoplastic agents. In American Hospital Formulary Services (AHFS) Drug Information. Bethesda, 2005, American Society of Health-System Pharmacists.
9. Trissel LA: Handbook on injectable drugs, ed 11. Bethesda, 2001, American Society of Health-System Pharmacists.
10. Olin BR (ed): Drug interactions. In Drug Facts and Comparisons. St Louis, 1992, Wolters Kluwer.
11. Hansten PD, Horn JR: Hansten and Horn’s managing clinically important drug interactions. Vancouver, 1998, Applied Therapeutics.
12. Fisher DS, Knobf MT, Durivage HJ: Drug interactions with antineoplastic agents. In: The cancer chemotherapy handbook, ed 4. St Louis, 1993, Mosby.

Section D: Chemotherapy Preparation

1. Blecher CS, Polovich M (eds): Safe handling of hazardous drugs. Pittsburgh, 2003, Oncology Nursing Society.
2. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Department of Health and Human Services: NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. DHHS (NIOSH) Publication No. 2004-165, 2004.
3. Connor TH, Sessink PJM, Harrison BR, et al: Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies, Am J Health Syst Pharm 62:475, 2005. Medline abstracts
4. Trissel LA (ed): Handbook on injectable drugs. Bethesda, 2005, American Society of Health-System Pharmacists.
5. Plumb DC (ed): Veterinary drug handbook. Ames, 2005, Iowa Sate Press.

Section E: Chemotherapy Administration

1. Kitchell BK, Orenberg EK, Brown DM, et al: Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma, Eur J Cancer 31A:2093, 1995. Medline abstracts
2. Kitchell BE, Brown DM, Luck EE, et al: Intralesional implant for treatment of primary oral malignant melanoma in dogs, J Am Vet Med Assoc 204:229, 1994. Medline abstracts
3. Yoshida K, Watarai Y, Sakai Y, et al: The effect of intralesional bleomycin on canine acanthomatous epulis, J Am Anim Hosp Assoc 34:457, 1998. Medline abstracts
4. Theon AP, Wilson WD, Magdesian KG, et al: Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995-2004), J Am Vet Med Assoc 230:1506, 2007. Medline abstracts
5. Moore AS, Kirk C, Cardona A: Intracavitary cisplatin chemotherapy experience with six dogs, J Vet Intern Med 5:227, 1991. Medline abstracts
6. Charney SC, Bergman PJ, McKnight JA, et al: Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997-2002), Vet Comp Oncol 3:171, 2005. Medline abstracts
7. Cahalane AK, Flanders JA, Steffey MA, et al: Use of vascular access ports with intrathoracic drains for treatment of pleural effusion in three dogs, J Am Vet Med Assoc 230:527, 2007. Medline abstracts
8. Henry CJ, Russell LE, Tyler JW, et al: Comparison of hematologic and biochemical values for blood samples obtained via jugular venipuncture and via vascular access ports in cats, J Am Vet Med Assoc 220:482, 2002. Medline abstracts
9. Evans KL, Smeak DD, Couto CG, et al: Comparison of two indwelling central venous access catheters in dogs undergoing fractionated radiotherapy, Vet Surg 23:135, 1994. Medline abstracts
10. Cahalane AK, Rassnick KM, Flanders JA: Use of vascular access ports in femoral veins of dogs and cats with cancer, J Am Vet Med Assoc 231:1354, 2007. Medline abstracts